Orthocell Seeks Trading Halt Ahead of Announcement on Remplir Regulatory Approval

MT Newswires Live

2024/10/07

Orthocell (ASX:OCC) requested a trading halt with the Australian bourse on Monday ahead of an announcement on the new regulatory approval for its peripheral nerve reconstruction device Remplir, according to a same-day filing with the Australian bourse.

The trading halt will remain until Wednesday or when the announcement is released, the filing said.

Before the halt, the regenerative medicine firm's shares rose to their highest since October 2022.

Price (AUD): $0.48, Change: $+0.020, Percent Change: +4.35%

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2473144465"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2473144465\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2473144465?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-07 13:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473144465","market":"fut","top_or_hot":-1,"title":"Orthocell Seeks Trading Halt Ahead of Announcement on Remplir Regulatory Approval","media":"MT Newswires Live","content":"<html><body><p> Orthocell (ASX:OCC) requested a trading halt with the Australian bourse on Monday ahead of an announcement on the new regulatory approval for its peripheral nerve reconstruction device Remplir, according to a same-day filing with the Australian bourse.</p><p>The trading halt will remain until Wednesday or when the announcement is released, the filing said.</p><p>Before the halt, the regenerative medicine firm's shares rose to their highest since October 2022.</p><p>Price (AUD): $0.48, Change: $+0.020, Percent Change: +4.35%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orthocell Seeks Trading Halt Ahead of Announcement on Remplir Regulatory Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthocell Seeks Trading Halt Ahead of Announcement on Remplir Regulatory Approval\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-10-07 13:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Orthocell (ASX:OCC) requested a trading halt with the Australian bourse on Monday ahead of an announcement on the new regulatory approval for its peripheral nerve reconstruction device Remplir, according to a same-day filing with the Australian bourse.</p><p>The trading halt will remain until Wednesday or when the announcement is released, the filing said.</p><p>Before the halt, the regenerative medicine firm's shares rose to their highest since October 2022.</p><p>Price (AUD): $0.48, Change: $+0.020, Percent Change: +4.35%</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XKO.AU","symbol_name":"標普/澳交所 300指數","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2473144465","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473144465","pubTimestamp":1728279643,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Orthocell  requested a trading halt with the Australian bourse on Monday ahead of an announcement on the new regulatory approval for its peripheral nerve reconstruction device Remplir, according to a same-day filing with the Australian bourse.The trading halt will remain until Wednesday or when the announcement is released, the filing said.Before the halt, the regenerative medicine firm's shares rose to their highest since October 2022.Price : $0.48, Change: $+0.020, Percent Change: +4.35%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XKO.AU":"标普/澳交所 300指数","XAO.AU":"标普/澳交所 普通股指数","BK7508":"医药生物股","BK7067":"生物科技","OCC.AU":"ORTHOCELL LTD","XJO.AU":"标普/澳交所 200指数","BK4125":"广播"},"translate_title":"Orthocell在宣布Remplir监管机构批准之前寻求暂停交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":0.9,"AUD":1,"OCC.AU":0.9,"XAO.AU":0.9,"XJO.AU":0.9},"content_text":"Orthocell (ASX:OCC) requested a trading halt with the Australian bourse on Monday ahead of an announcement on the new regulatory approval for its peripheral nerve reconstruction device Remplir, according to a same-day filing with the Australian bourse.The trading halt will remain until Wednesday or when the announcement is released, the filing said.Before the halt, the regenerative medicine firm's shares rose to their highest since October 2022.Price (AUD): $0.48, Change: $+0.020, Percent Change: +4.35%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}